Show simple item record

Article

dc.creatorVillegas Lama, Isabeles
dc.creatorRosillo Ramírez, María de los Ángeleses
dc.creatorAlarcón de la Lastra Romero, Catalinaes
dc.creatorVázquez Román, María Victoriaes
dc.creatorLlorente, Maríaes
dc.creatorSánchez, Susanaes
dc.creatorFernández Campos, Franciscoes
dc.date.accessioned2021-02-12T09:59:24Z
dc.date.available2021-02-12T09:59:24Z
dc.date.issued2021-01
dc.identifier.citationVillegas Lama, I., Rosillo Ramírez, M.d.l.Á., Alarcón de la Lastra Romero, C., Vázquez Román, M.V., Llorente, M., Sánchez, S. y Fernández Campos, F. (2021). Amoxicillin and Clarithromycin Mucoadhesive Delivery System for Helicobacter pylori Infection in a Mouse Model: Characterization, Pharmacokinetics, and Efficacy. Pharmaceutics, 13 (2), 153.
dc.identifier.issn1999-4923es
dc.identifier.urihttps://hdl.handle.net/11441/104881
dc.description.abstractHelicobacter pylori is the main pathogen responsible for gastric ulcers and a predisposing factor of stomach cancer. Although current treatment is usually successful, it requires high doses and frequent administration. An innovative mucoadhesive system (Mucolast®) loaded with amoxicillin and clarithromycin is proposed to improve the efficacy of treatment against H. pylori. The drug product was optimized based on its viscoelastic properties to obtain long-term stability of the vehicle. The drug release mechanisms were different for both antibiotics based on their solubilization status. A systemic and stomach pharmacokinetic profile was obtained after three different doses were administered to mice, obtaining similar systemic exposure levels but an increase in drug concentration in the stomach. The efficacy results in mice infected with H. pylori also demonstrated the superiority of the antibiotics when administered in Mucolast®, as shown by the bacterial count in stomach tissue and under histopathological and biochemical evaluation. The proposed treatment was efficacious and safe and is presented as a realistic alternative to current treatment options to improve patient compliance and to reduce bacterial resistance.es
dc.description.sponsorshipMinisterio de Ciencia e Innovación. Gobierno de España (programa RETOS)-RTC-2015-4437-1es
dc.formatapplication/pdfes
dc.format.extent25 p.es
dc.language.isoenges
dc.publisherMDPIes
dc.relation.ispartofPharmaceutics, 13 (2), 153.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHelicobacter pylories
dc.subjectmucoadhesivees
dc.subjectclarithromycines
dc.subjectamoxicillines
dc.subjectmicees
dc.subjectpharmacokineticses
dc.subjectMucolast®es
dc.titleAmoxicillin and Clarithromycin Mucoadhesive Delivery System for Helicobacter pylori Infection in a Mouse Model: Characterization, Pharmacokinetics, and Efficacyes
dc.typeinfo:eu-repo/semantics/articlees
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Farmacologíaes
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Citología e Histología Normal y Patológicaes
dc.relation.projectIDRTC-2015-4437-1es
dc.relation.publisherversionhttps://doi.org/10.3390/pharmaceutics13020153es
dc.identifier.doi10.3390/pharmaceutics13020153es
dc.journaltitlePharmaceuticses
dc.publication.volumen13es
dc.publication.issue2es
dc.publication.initialPage153es
dc.contributor.funderMinisterio de Ciencia e Innovación (MICIN). Españaes

FilesSizeFormatViewDescription
pharmaceutics-13-00153-v2.pdf4.392MbIcon   [PDF] View/Open  

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as: Attribution-NonCommercial-NoDerivatives 4.0 Internacional